HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neutralizing Concentrations of Anti-Botulinum Toxin Antibodies Positively Correlate with Mouse Neutralization Assay Results in a Guinea Pig Model.

Abstract
Botulinum neurotoxins (BoNT) are some of the most toxic proteins known and can induce respiratory failure requiring long-term intensive care. Treatment of botulism includes the administration of antitoxins. Monoclonal antibodies (mAbs) hold considerable promise as BoNT therapeutics and prophylactics, due to their potency and safety. A three-mAb combination has been developed that specifically neutralizes BoNT serotype A (BoNT/A), and a separate three mAb combination has been developed that specifically neutralizes BoNT serotype B (BoNT/B). A six mAb cocktail, designated G03-52-01, has been developed that combines the anti-BoNT/A and anti-BoNT/B mAbs. The pharmacokinetics and neutralizing antibody concentration (NAC) of G03-52-01 has been determined in guinea pigs, and these parameters were correlated with protection against an inhalation challenge of BoNT/A1 or BoNT/B1. Previously, it was shown that each antibody demonstrated a dose-dependent mAb serum concentration and reached maximum circulating concentrations within 48 h after intramuscular (IM) or intraperitoneal (IP) injection and that a single IM injection of G03-52-01 administered 48 h pre-exposure protected guinea pigs against an inhalation challenge of up to 93 LD50s of BoNT/A1 and 116 LD50s of BoNT/B1. The data presented here advance our understanding of the relationship of the neutralizing NAC to the measured circulating antibody concentration and provide additional support that a single IM or intravenous (IV) administration of G03-52-01 will provide pre-exposure prophylaxis against botulism from an aerosol exposure of BoNT/A and BoNT/B.
AuthorsMilan T Tomic, Shauna Farr-Jones, Emily S Syar, Nancy Niemuth, Dean Kobs, Michael J Hackett, Yero Espinoza, Zacchary Martinez, Khanh Pham, Doris M Snow, James D Marks, Ronald R Cobb
JournalToxins (Toxins (Basel)) Vol. 13 Issue 9 (09 21 2021) ISSN: 2072-6651 [Electronic] Switzerland
PMID34564675 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antitoxins
  • Drug Combinations
  • Botulinum Toxins
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antibodies, Neutralizing (immunology, therapeutic use)
  • Antitoxins (immunology, therapeutic use)
  • Botulinum Toxins (toxicity)
  • Botulism (drug therapy)
  • Clostridium botulinum (genetics)
  • Disease Models, Animal
  • Drug Combinations
  • Guinea Pigs
  • Mice
  • Serogroup

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: